A glimpse into immune responses evolving against Ebola virus

Antibodies elicited by the widely deployed rVSV-EBOV Ebola virus vaccine mirror those of disease survivors, animal models and other vaccine platforms. Notably, neutralizing antibodies are consistently elicited from a recurring pair of germline genes.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1


  1. 1.

    Ehrhardt, S. A. Nat. Med. s41591-019-0602-4 (2019).

  2. 2.

    Corti, D. et al. Science 351, 1339–1342 (2016).

    CAS  Article  Google Scholar 

  3. 3.

    Misasi, J. et al. Science 351, 1343–1346 (2016).

    CAS  Article  Google Scholar 

  4. 4.

    Davis, C. W. et al. Cell 177, 1566–1582 (2019).

    CAS  Article  Google Scholar 

  5. 5.

    Saphire, E. O. et al. Cell 174, 938–952 (2018).

    CAS  Article  Google Scholar 

  6. 6.

    Bornholdt, Z. A. et al. Science 351, 1078–1083 (2016).

    CAS  Article  Google Scholar 

  7. 7.

    Rijal, P. et al. Cell Rep. 27, 172–186.e7 (2019).

    CAS  Article  Google Scholar 

  8. 8.

    Henao-Restrepo, A. M. et al. Lancet 389, 505–518 (2017).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Erica Ollmann Saphire.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Saphire, E.O. A glimpse into immune responses evolving against Ebola virus. Nat Med 25, 1470–1471 (2019).

Download citation